Semaglutide.
S💡 Explain this simply
Semaglutide is an approved drug in the glp-1 & incretin receptor agonists.
It draws interest for glp-1 & incretin receptor agonists and is prescribed for its approved indication(s).
Yes for its approved use(s), with caveats — strong human trial evidence underpins the label, but broader wellness/longevity claims are not proven.
Uses beyond its approved indication(s); General anti-aging or longevity; Unsupervised wellness experimentation.
A clinically validated drug for its lane; outside that lane, treat broader claims with caution.
Before you decide, compare Semaglutide with Liraglutide, Tirzepatide, Retatrutide. See all →
Semaglutide is an approved drug in the glp-1 & incretin receptor agonists.
Activating the GLP-1 receptor to enhance insulin release, slow gastric emptying, and reduce appetite.
It draws interest for glp-1 & incretin receptor agonists and is prescribed for its approved indication(s).
Yes for its approved use(s), with caveats — strong human trial evidence underpins the label, but broader wellness/longevity claims are not proven.
A GLP-1 receptor agonist with large randomized human trials behind it. The STEP program studied it for chronic weight management and SUSTAIN for type-2 diabetes; it is FDA-approved (Wegovy, Ozempic). The strongest weight/glucose evidence of any compound in this space — with well-documented GI side effects and the need for ongoing use.
Verified citations resolve to PubMed / FDA. See how we score.
Semaglutide: the research file
What it is
Semaglutide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist — an acylated, structurally modified analog of the native incretin hormone GLP-1, engineered for once-weekly (injectable) or daily (oral) dosing through albumin binding and resistance to DPP-4 degradation. It is a fully approved prescription medicine marketed as Ozempic and Rybelsus (type 2 diabetes) and Wegovy (chronic weight management and, more recently, cardiovascular risk reduction). It is one of the most extensively studied peptide therapeutics in modern medicine, with large dedicated cardiovascular- and liver-outcome trials.
How it works
Semaglutide binds and activates the GLP-1 receptor, a G-protein-coupled receptor expressed on pancreatic beta cells, the central nervous system, and elsewhere. In the pancreas it augments glucose-dependent insulin secretion and suppresses glucagon, lowering blood glucose with low intrinsic hypoglycemia risk because the effect is glucose-dependent. Centrally, it acts on hypothalamic and hindbrain appetite circuits to increase satiety and reduce food intake, and it slows gastric emptying — the combination drives weight loss. The molecule's C18 fatty-diacid side chain promotes albumin binding, which extends its half-life to roughly a week and underlies once-weekly dosing.
What the evidence shows
Human evidence is exceptionally strong and trial-backed rather than preclinical. The STEP 1 randomized trial (NEJM 2021, PMID 33567185) showed substantial, clinically meaningful weight loss versus placebo in adults with overweight/obesity without diabetes. SUSTAIN-6 (NEJM 2016, PMID 27633186) demonstrated reduced major adverse cardiovascular events in type 2 diabetes, and SELECT (NEJM 2023, PMID 37952131) showed a significant reduction in cardiovascular death, myocardial infarction, or stroke in people with obesity and established cardiovascular disease but without diabetes. The phase 3 ESSENCE trial (NEJM 2025, PMID 40305708) reported improvement in metabolic dysfunction-associated steatohepatitis (MASH). A documented limitation: the STEP 1 extension (Diabetes Obes Metab 2022, PMID 35441470) showed substantial weight regain after discontinuation, indicating benefits depend on continued use.
Safety considerations
The most common documented adverse effects are gastrointestinal — nausea, vomiting, diarrhea, and constipation — typically most pronounced early in treatment. Labeled warnings include a boxed warning for thyroid C-cell tumors based on rodent data (clinical relevance in humans remains uncertain), plus risks of pancreatitis, gallbladder disease, acute kidney injury from dehydration, and diabetic retinopathy complications in susceptible patients. Reduced lean mass alongside fat loss, and weight regain after stopping, are recognized. Use of unregulated, compounded, or research-grade "semaglutide" sold outside the approved supply chain carries additional, poorly characterized risks of contamination, mislabeling, and dosing errors.
Regulatory status
Semaglutide is FDA-approved (not investigational): Ozempic and Rybelsus for type 2 diabetes with cardiovascular risk-reduction indications, and Wegovy for chronic weight management and for cardiovascular risk reduction in adults with cardiovascular disease and overweight/obesity. Oral semaglutide for chronic weight management and a MASH indication are the most recent regulatory developments.
- GLP-1 receptor agonist; an acylated analog of native GLP-1 engineered for extended half-life
- Sold as Ozempic and Rybelsus (diabetes) and Wegovy (weight management/CV risk)
- SELECT was the landmark trial showing cardiovascular benefit in obesity without diabetes
- Effects on weight are not durable after stopping — STEP 1 extension showed significant regain
- Carries a boxed warning for thyroid C-cell tumors based on rodent studies
- Available in once-weekly injectable and daily oral formulations
- [1]Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1) — New England Journal of Medicine, 2021, PMID 33567185
- [2]Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT) — New England Journal of Medicine, 2023, PMID 37952131
- [3]Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6) — New England Journal of Medicine, 2016, PMID 27633186
- [4]Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis (ESSENCE) — New England Journal of Medicine, 2025, PMID 40305708
Currently sits at Approved use — FDA-approved for a specific indication — the strongest lane.
Jargon, decoded: · · ·
Areas this compound is studied or discussed for — not guaranteed effects.
- Semaglutide is a GLP-1 receptor agonist — an incretin mimetic that enhances glucose-dependent insulin secretion, slows gastric emptying, and reduces appetite.
- It is FDA-approved (brands include Ozempic, Wegovy, Rybelsus) for type-2 diabetes and chronic weight management, backed by large human trials (the SUSTAIN and STEP programs).
- It has a long half-life of roughly one week — the pharmacologic basis for the once-weekly approved injectable formulations.
- Strong evidence for its approved uses; longevity/anti-aging extrapolations are not approved or proven.
- Common effects are gastrointestinal (nausea, etc.); see the FDA label for warnings and contraindications.
Marketing claim vs what the data actually shows. Tap a row for detail.
Verdicts describe the state of the evidence, not invented study results. Open References for the underlying citations.
Stack fit
Decision clarity: HighClear evidence lane, known safety, and regulatory clarity.
Stack verdict: A clinically validated drug for its lane; outside that lane, treat broader claims with caution.
Semaglutide is not established for:
Tier ranking
A weighted evidence score of 95/100 places semaglutide in S tier — based on published evidence, not popularity.
Weighted evidence score 95/100
Why not A: supported by human evidence, preclinical depth, mechanism confidence, safety clarity, regulatory clarity, practical relevance.
What would move it up: Larger controlled human trials, clearer long-term safety, replicated findings, and regulatory progress.
What would move it down: Failed confirmatory trials, new safety signals, or evidence that popular claims don't translate.
- Semaglutide is an FDA-approved drug for specific indications.
- It belongs to the GLP-1 & incretin receptor agonists class.
- Its principal mechanism is characterized in the literature.
- Long-term safety in healthy users, and full drug-interaction risk.
- Claim-by-claim verdicts — these are authored against verified sources and shown when complete.
This is not medical advice. These are areas where professional guidance and better evidence matter most.
See it next to its closest alternatives.
Full brief
A deeper, chapter-by-chapter research briefing. Tap any chapter to expand.
- What it is
- The GLP-1 receptor agonism mechanism
- The approval lane
- Why Established, and not higher or lower
- Proven lane vs speculative lane
- What people report
- Regulatory status
- What changed recently
01What it is
Simple takeaway: Semaglutide is an approved drug in the glp-1 & incretin receptor agonists.
Peptides that mimic incretin hormones to influence insulin secretion, gastric emptying, and appetite. This class includes the approved metabolic drugs and newer multi-receptor agonists. It has been through human clinical development for its approved indication(s).
02The GLP-1 receptor agonism mechanism
Simple takeaway: Activating the GLP-1 receptor to enhance insulin release, slow gastric emptying, and reduce appetite.
GLP-1 receptor agonists mimic the incretin hormone GLP-1. Activation increases glucose-dependent insulin secretion (so insulin rises mainly when glucose is high), slows the rate at which the stomach empties, and acts on central pathways that reduce appetite. This combination underpins their use in glucose control and weight management.
03The approval lane
Simple takeaway: Semaglutide's strongest evidence is its FDA-approved use.
Approved (Ozempic, Wegovy, Rybelsus) for type 2 diabetes and chronic weight management.
04Why Established, and not higher or lower
Simple takeaway: Composite maturity 4.8/5.
What holds it back: remaining gaps and limited replication. What supports its placement: human evidence, preclinical depth, mechanism confidence, safety clarity, regulatory clarity, practical relevance. Stronger human trials, clearer long-term safety data, and regulatory progress would move it up; a safety signal or failure to replicate would move it down.
05Proven lane vs speculative lane
Simple takeaway: The approved use is real; broader wellness claims are extrapolation.
What's proven is the approved indication, supported by trials. What's speculative is the longevity/wellness extrapolation that isn't on the label and hasn't been demonstrated for those uses.
06What people report
Simple takeaway: Community reports are not clinical evidence.
Online reports can surface expectation patterns and possible safety signals, but they are shaped by placebo effects, selection bias, confounders, and uncertain product quality and sourcing. We don't treat anecdotes as proof and we don't publish dosing or protocols.
07Regulatory status
Simple takeaway: FDA-approved
Approved (Ozempic, Wegovy, Rybelsus) for type 2 diabetes and chronic weight management. Regulatory status can change and differs by country; several peptides are also prohibited in sport (WADA). Verify current status before relying on it.
08What changed recently
Simple takeaway: No major evidence-changing update was identified in this review window.
The current profile reflects the existing body of indexed evidence. Material changes — new trials, approvals, or safety findings — are noted here when an editor logs them.
How the community sees this vs the evidence.
Evidence tier is S. Do you agree?
Community votes reflect user perception, not scientific proof — the evidence tier comes from our Research Maturity Index. Aggregate community sentiment will appear here once enough votes are collected.
Aggregate community sentiment will appear here once enough votes are in — we don't show invented numbers.
Get notified when new studies, safety updates, regulatory changes, or the tier ranking change.
FAQs
Is Semaglutide FDA-approved?
Yes — Semaglutide is FDA-approved for specific medical indications. Approved (Ozempic, Wegovy, Rybelsus) for type 2 diabetes and chronic weight management.
What is Semaglutide studied for?
Semaglutide is studied mainly for weight loss. Peptides that mimic incretin hormones to influence insulin secretion, gastric emptying, and appetite. This class includes the approved metabolic drugs and newer multi-receptor agonists.
What does the research say about Semaglutide?
Clinically validated. Approved for medical use, with strong human evidence and characterized safety for its indications.
Is Semaglutide safe?
It has documented safety for its approved use; off-label and long-term safety are less certain. Quality and purity from non-pharmaceutical sources is an added risk.
🧮 Reconstitution calculator (educational)
Educational reconstitution math from your own values — not medical advice or a dose recommendation. Open the full calculator →
Each unit on a 100u · 1.0 mL syringe ≈ 25 mcg of this solution.
Show the math
More water → lower concentration → more units for the same amount.
Get the vial, water, target, and 10-unit draw sent to your inbox so it's easy to reference — and follow when the evidence changes. Free, no account.
Research reference only. Not medical advice, treatment instructions, or a purchase recommendation. Consult a licensed professional.